ArticleMolecular therapy. Oncology2025

CircSPINT2 confers sensitivity to osimertinib via hsa-miR-1296-3p/RBP1 axis and inhibits NSCLC progression.

Nalini Devi Verusingam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.